Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis

[21] Gotzsche PC(2019)Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017 Nature 8 e24-1861

[22] Ioannidis JP(2021)Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses J Med Virol. 253 117592-590

[23] Munn Z(2021)Risk of adverse coronavirus disease 2019 outcomes for people living with HIV AIDS 13 1856-248

[24] Barker TH(2021)HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform Lancet HIV 61 581-732

[25] Moola S(2020)Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study Life Sci 34 247-60

[26] Tufanaru C(2020)Raltegravir, indinavir, tipranavir, dolutegravir, and etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: a molecular docking and drug repurposing approach J Infect Public Health 93 726-92

[27] Stern C(2021)Antiretrovirals for prophylaxis against COVID-19: a comprehensive literature review J Clin Pharmacol 93 59-1720

[28] McArthur A(2020)Why aren't people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)? AIDS Patient Care STDS 25 85-16

[29] Higgins J(2021)HIV/SARS-CoV-2 coinfection: a global perspective J Med Virol. 382 1708-2938

[30] Thompson S(2021)Living with HIV in the time of COVID-19: a glimpse of hope J Med Virol 190 10-e520

[21] Gotzsche PC(2019)Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017 Nature 8 e24-1861

[22] Ioannidis JP(2021)Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses J Med Virol. 253 117592-590

[23] Munn Z(2021)Risk of adverse coronavirus disease 2019 outcomes for people living with HIV AIDS 13 1856-248

[24] Barker TH(2021)HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform Lancet HIV 61 581-732

[25] Moola S(2020)Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study Life Sci 34 247-60

[26] Tufanaru C(2020)Raltegravir, indinavir, tipranavir, dolutegravir, and etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: a molecular docking and drug repurposing approach J Infect Public Health 93 726-92

[27] Stern C(2021)Antiretrovirals for prophylaxis against COVID-19: a comprehensive literature review J Clin Pharmacol 93 59-1720

[28] McArthur A(2020)Why aren't people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)? AIDS Patient Care STDS 25 85-16

[29] Higgins J(2021)HIV/SARS-CoV-2 coinfection: a global perspective J Med Virol. 382 1708-2938

[30] Thompson S(2021)Living with HIV in the time of COVID-19: a glimpse of hope J Med Virol 190 10-e520